Status:
TERMINATED
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous o...
Eligibility Criteria
Inclusion
- Completed study drug treatment in a parent study; or had study drug interruption(s) in a parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study.
Exclusion
- History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator.
- Current participation in an investigational drug trial (other than a parent study)
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
July 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2020
Estimated Enrollment :
484 Patients enrolled
Trial Details
Trial ID
NCT03447262
Start Date
July 13 2018
End Date
September 9 2020
Last Update
January 25 2022
Active Locations (100)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Stanford University
Palo Alto, California, United States, 94304
3
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
4
Hartford Hospital
Hartford, Connecticut, United States, 06102